$3.05
4.10% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Stock price

$3.05
+0.30 10.91% 1M
-1.61 34.55% 6M
-1.07 25.97% YTD
-3.73 55.01% 1Y
-14.29 82.41% 3Y
-32.00 91.30% 5Y
-32.00 91.30% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.12 4.10%
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Key metrics

Market capitalization $522.91m
Enterprise Value $-140.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.51
EV/Sales (TTM) EV/Sales -18.27
P/S ratio (TTM) P/S ratio 68.09
P/B ratio (TTM) P/B ratio 0.72
Revenue growth (TTM) Revenue growth -78.26%
Revenue (TTM) Revenue $7.68m
EBIT (operating result TTM) EBIT $-378.35m
Free Cash Flow (TTM) Free Cash Flow $-272.62m
Cash position $710.36m
EPS (TTM) EPS $-2.23
P/E forward negative
P/S forward 43.80
EV/Sales forward negative
Short interest 13.89%
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Relay Therapeutics Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.68 7.68
78% 78%
100%
- Direct Costs 5.28 5.28
3% 3%
69%
2.40 2.40
92% 92%
31%
- Selling and Administrative Expenses 65 65
1% 1%
846%
- Research and Development Expense 311 311
6% 6%
4,043%
-373 -373
3% 3%
-4,858%
- Depreciation and Amortization 5.28 5.28
3% 3%
69%
EBIT (Operating Income) EBIT -378 -378
2% 2%
-4,926%
Net Profit -333 -333
1% 1%
-4,341%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
12 days ago
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:
Neutral
GlobeNewsWire
15 days ago
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents ...
Neutral
GlobeNewsWire
22 days ago
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025.
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 261
Founded 2015
Website www.relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today